We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| DICE Therapeutics Inc | NASDAQ:DICE | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 47.55 | 49.96 | 47.99 | 0 | 01:00:00 |
From May 2023 to May 2024
09:45 ET -- Eli Lilly is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. Eli Lilly said Tuesday it is paying $48 a share of DICE Therapeutics to buy the smaller biopharmaceutical company for $2.4 billion, which would represent a premium of about 40% to DICE's 30-day volume-weighted average trading price up to its last trading day on Friday. The transaction is expected to close in the third quarter of this year. Dow Jones & Co. owns Factiva. (chris.wack@wsj.com)
(END) Dow Jones Newswires
June 20, 2023 10:00 ET (14:00 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year DICE Therapeutics Chart |
1 Month DICE Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
